OncoHost Research Demonstrates Plasma Proteomics Can Predict Immunotherapy Resistance in NSCLC Patients
OncoHost has announced new research findings to be presented at the International Society of Liquid Biopsy (ISLB) meeting. The study validates a 22-protein plasma signature capable of monitoring immunotherapy response and predicting overall survival in patients with advanced non-small cell lung cancer (NSCLC). The data reveals that this proteomic profiling can detect disease progression a median of 170 days—approximately 5.6 months—before it is visible via conventional radiologic assessment. By analyzing serial blood samples, the signature identifies emerging treatment resistance and correlates strongly with clinical outcomes, offering a potential liquid biopsy alternative for continuous patient monitoring.
Topics: biomarkers immunotherapy response non-small cell lung cancer precision oncology proteomics